Pathophysiology of sepsis and recent patents on the diagnosis, treatment and prophylaxis for sepsis

Yasumasa Okazaki, Akihiro Matsukawa

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Despite advances in the development of powerful antibiotics and intensive care unit, sepsis is still life threatening and the mortality rate remains unchanged for the past three decades. Recent prospective trials with biological response modifiers have shown a modest clinical benefit. The pathological basis of sepsis is initially an excessive inflammatory response against invading pathogens, leading to systemic inflammatory response syndrome (SIRS). Evidence reveals that a variety of inflammatory mediators orchestrate the intense inflammation through complicated cellular interactions. More recent data indicate that most septic patients survive this stage and then subjected to an immunoparalysis phase, termed compensatory anti-inflammatory response syndrome (CARS), which is more fatal than the initial phase. Sepsis is a complicated clinical syndrome with multiple physiologic and immunologic abnormalities. In this review, we summarize the recent understandings of the pathophysiology of sepsis, and introduce recent patents on diagnosis, treatment and prophylaxis for sepsis.

Original languageEnglish
Pages (from-to)26-32
Number of pages7
JournalRecent Patents on Inflammation and Allergy Drug Discovery
Volume3
Issue number1
DOIs
Publication statusPublished - 2009

Fingerprint

Patents
Sepsis
Therapeutics
Systemic Inflammatory Response Syndrome
Immunologic Factors
Intensive Care Units
Anti-Inflammatory Agents
Anti-Bacterial Agents
Inflammation
Mortality

Keywords

  • Anti-inflammatory response syndrome
  • Multiple organ failure
  • Sepsis
  • Septic shock
  • Systemic inflammatory response syndrome

ASJC Scopus subject areas

  • Drug Discovery
  • Immunology and Allergy

Cite this

@article{f6a2a9d2fada4dd79a89c15d8efce3c2,
title = "Pathophysiology of sepsis and recent patents on the diagnosis, treatment and prophylaxis for sepsis",
abstract = "Despite advances in the development of powerful antibiotics and intensive care unit, sepsis is still life threatening and the mortality rate remains unchanged for the past three decades. Recent prospective trials with biological response modifiers have shown a modest clinical benefit. The pathological basis of sepsis is initially an excessive inflammatory response against invading pathogens, leading to systemic inflammatory response syndrome (SIRS). Evidence reveals that a variety of inflammatory mediators orchestrate the intense inflammation through complicated cellular interactions. More recent data indicate that most septic patients survive this stage and then subjected to an immunoparalysis phase, termed compensatory anti-inflammatory response syndrome (CARS), which is more fatal than the initial phase. Sepsis is a complicated clinical syndrome with multiple physiologic and immunologic abnormalities. In this review, we summarize the recent understandings of the pathophysiology of sepsis, and introduce recent patents on diagnosis, treatment and prophylaxis for sepsis.",
keywords = "Anti-inflammatory response syndrome, Multiple organ failure, Sepsis, Septic shock, Systemic inflammatory response syndrome",
author = "Yasumasa Okazaki and Akihiro Matsukawa",
year = "2009",
doi = "10.2174/187221309787158416",
language = "English",
volume = "3",
pages = "26--32",
journal = "Recent Patents on Inflammation and Allergy Drug Discovery",
issn = "1872-213X",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Pathophysiology of sepsis and recent patents on the diagnosis, treatment and prophylaxis for sepsis

AU - Okazaki, Yasumasa

AU - Matsukawa, Akihiro

PY - 2009

Y1 - 2009

N2 - Despite advances in the development of powerful antibiotics and intensive care unit, sepsis is still life threatening and the mortality rate remains unchanged for the past three decades. Recent prospective trials with biological response modifiers have shown a modest clinical benefit. The pathological basis of sepsis is initially an excessive inflammatory response against invading pathogens, leading to systemic inflammatory response syndrome (SIRS). Evidence reveals that a variety of inflammatory mediators orchestrate the intense inflammation through complicated cellular interactions. More recent data indicate that most septic patients survive this stage and then subjected to an immunoparalysis phase, termed compensatory anti-inflammatory response syndrome (CARS), which is more fatal than the initial phase. Sepsis is a complicated clinical syndrome with multiple physiologic and immunologic abnormalities. In this review, we summarize the recent understandings of the pathophysiology of sepsis, and introduce recent patents on diagnosis, treatment and prophylaxis for sepsis.

AB - Despite advances in the development of powerful antibiotics and intensive care unit, sepsis is still life threatening and the mortality rate remains unchanged for the past three decades. Recent prospective trials with biological response modifiers have shown a modest clinical benefit. The pathological basis of sepsis is initially an excessive inflammatory response against invading pathogens, leading to systemic inflammatory response syndrome (SIRS). Evidence reveals that a variety of inflammatory mediators orchestrate the intense inflammation through complicated cellular interactions. More recent data indicate that most septic patients survive this stage and then subjected to an immunoparalysis phase, termed compensatory anti-inflammatory response syndrome (CARS), which is more fatal than the initial phase. Sepsis is a complicated clinical syndrome with multiple physiologic and immunologic abnormalities. In this review, we summarize the recent understandings of the pathophysiology of sepsis, and introduce recent patents on diagnosis, treatment and prophylaxis for sepsis.

KW - Anti-inflammatory response syndrome

KW - Multiple organ failure

KW - Sepsis

KW - Septic shock

KW - Systemic inflammatory response syndrome

UR - http://www.scopus.com/inward/record.url?scp=61449149742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61449149742&partnerID=8YFLogxK

U2 - 10.2174/187221309787158416

DO - 10.2174/187221309787158416

M3 - Article

C2 - 19149743

AN - SCOPUS:61449149742

VL - 3

SP - 26

EP - 32

JO - Recent Patents on Inflammation and Allergy Drug Discovery

JF - Recent Patents on Inflammation and Allergy Drug Discovery

SN - 1872-213X

IS - 1

ER -